US Pricing vs. Global Excellence: Navigating Affordable, World-Class Cancer Surgeries

1. Why US Cancer Surgery Costs Are Forcing Patients to Look Abroad for Solutions

A cancer diagnosis is one of the most frightening moments in a person's life. For millions of adults across North America and Europe, that fear is immediately compounded by a second, equally urgent crisis: the staggering financial cost of treatment. In the United States, the average cost of cancer care in the first year following diagnosis ranges from $80,000 to well over $300,000, depending on cancer type, surgical complexity, and treatment setting. For patients without comprehensive insurance — or whose insurance imposes significant deductibles, co-pays, and lifetime caps — these figures can be catastrophic.

A landmark study published in the American Journal of Medicine found that more than 42% of cancer patients in the United States deplete their entire life savings within two years of diagnosis. The term "financial toxicity" has entered the clinical vocabulary because researchers now recognize that the economic burden of cancer treatment directly harms patient outcomes — patients who face catastrophic costs are more likely to delay treatment, skip follow-up appointments, and experience the kind of chronic stress that impairs immune function and recovery.

For European patients, the picture is more nuanced but not necessarily better. While national health systems provide a baseline, access to the most advanced surgical technologies — robotic-assisted procedures, minimally invasive oncological resections, and specialized reconstructive techniques — is often rationed by cost-effectiveness thresholds. Waiting lists for elective cancer surgery in countries like the UK, Canada, and several EU nations regularly extend to months, during which time tumors may progress and the window for optimal surgical outcomes narrows.

It is in this context that overseas oncology surgery has moved from a niche consideration to a genuinely mainstream healthcare decision. Patients across North America and Europe are increasingly asking a straightforward question: if I can receive the same — or better — surgical care at an internationally accredited hospital in China, at 60–70% less cost, with no waiting list, why would I not consider it? This guide exists to help you answer that question with clear, honest, evidence-based information.

1.1 The Hidden Costs of Staying Home: Beyond the Surgical Bill

When North American patients calculate the cost of cancer surgery at home, they often focus on the sticker price of the procedure itself. But the true financial burden extends far beyond the operating room. Consider the cascade of costs that accompany major oncological surgery in the United States: pre-operative diagnostic imaging and specialist consultations ($5,000–$20,000), the surgical procedure itself ($30,000–$150,000+), anesthesiology fees billed separately ($3,000–$15,000), hospital room and board during recovery ($2,000–$5,000 per day), post-operative pathology and molecular testing ($3,000–$8,000), and adjuvant treatment planning consultations. For patients who require reconstructive surgery — common after breast, colorectal, or head-and-neck cancer resections — additional costs of $20,000–$80,000 are typical.

Insurance coverage for each of these components varies dramatically. Patients discover, often at the worst possible moment, that their insurer considers certain procedures "investigational," certain facilities "out of network," or certain specialists "not covered." The administrative burden of navigating these disputes — while simultaneously recovering from major surgery and cancer treatment — is a form of suffering that does not appear in clinical statistics but is deeply real for the families who experience it.

At China's leading oncology centers — accessible through MedBridge's vetted partner network — all costs are disclosed upfront in a single itemized package. There are no surprise bills, no separate anesthesiology invoices, no facility fees billed months after discharge. The price transparency alone represents a meaningful reduction in the psychological burden of treatment, independent of the financial savings.

1.2 The Growing Community of Medical Travelers Seeking Cancer Surgery Abroad

The decision to seek cancer surgery abroad is no longer unusual or desperate. It is being made by educated, research-oriented patients — many of them professionals, academics, and healthcare workers themselves — who have done rigorous due diligence and concluded that the quality of care available at internationally accredited hospitals in Asia, particularly China, is genuinely comparable to leading Western centers for many cancer types.

Online communities on platforms like Reddit (r/cancer, r/medicaltourism), Patient Advocate Foundation forums, and dedicated medical tourism support groups now contain thousands of first-hand accounts from North American and European patients who have received cancer surgery in China and returned home with documented outcomes, pathology reports, and follow-up records that their home oncologists have reviewed and accepted. MedBridge exists to make that process safer, more transparent, and more effectively supported for every patient who considers it.

1.2.1 The Role of Currency and Healthcare Economics in the Price Gap

A frequently asked question is: how can a hospital that offers cancer surgery at 60–70% less than a US facility be genuinely delivering equivalent quality? The answer lies in healthcare economics, not quality compromise. Physician compensation in China, while generous by local standards, is a fraction of what American surgeons earn — not because Chinese surgeons are less skilled, but because the cost of living, malpractice insurance premiums, and healthcare administration overhead are dramatically lower. Hospital construction costs, equipment acquisition, and operational expenses are similarly lower relative to China's economic base. The result is that the same DaVinci robotic surgical system, the same pathology laboratory equipment, and the same internationally trained surgical team can be deployed at a fundamentally different price point without any reduction in clinical quality.

2. What "World-Class" Cancer Surgery Actually Means in Global Terms

The phrase "world-class" is used so freely in healthcare marketing that it has lost much of its meaning. For patients making life-or-death decisions about cancer surgery, vague assurances are not sufficient. What does world-class actually mean in measurable, verifiable terms — and how do China's leading oncology centers perform against those standards?

True excellence in cancer surgery is defined by a specific set of measurable outcomes and structural characteristics. These include: negative surgical margin rates (the proportion of surgeries in which cancer is completely removed with clear margins), lymph node yield (the number of lymph nodes harvested during staging procedures, which directly affects the accuracy of cancer staging), complication rates (including infection, anastomotic leak, bleeding, and organ injury), 30-day readmission rates, length of hospital stay, time to recovery of function, and long-term disease-free survival rates at 1, 3, and 5 years post-surgery.

These are the metrics that distinguish genuinely excellent cancer surgery from merely adequate surgery. And it is against these metrics — not marketing materials or accreditation certificates — that China's leading oncology centers must be evaluated.

2.1 Clinical Outcome Standards: How China's Top Centers Measure Up

The peer-reviewed literature on surgical oncology outcomes at China's leading hospitals has grown substantially over the past decade. Publications in The Lancet Oncology, the Journal of Clinical Oncology, Cancer, and Annals of Surgery have documented outcomes from China's major cancer centers that are directly comparable to — and in several specific areas, superior to — outcomes reported by leading Western institutions.

• Colorectal cancer surgery: Several Chinese academic centers have published total mesorectal excision (TME) completion rates and circumferential resection margin (CRM) positivity rates that meet or exceed the benchmarks set by European TME standards programs. For rectal cancer surgery specifically — among the most technically demanding oncological procedures — China's specialist centers have accumulated enormous case volumes that translate into refined surgical precision.
• Gastric cancer surgery: China has the world's highest burden of gastric cancer by absolute case number, which has driven the development of unparalleled surgical expertise. D2 gastrectomy — the gold-standard nodal dissection for gastric cancer — is performed routinely and with low morbidity at China's leading gastric cancer centers, where surgeons may perform more D2 gastrectomies in a single year than many Western surgeons perform in a career.
• Hepatocellular carcinoma (liver cancer): China's liver surgery centers lead the world in published experience with complex liver resections, including major hepatectomies, associating liver partition and portal vein ligation (ALPPS), and robotic liver surgery. The combination of high case volume and continuous technical refinement has produced outcomes data that is internationally recognized.
• Lung cancer surgery: Robotic-assisted thoracic surgery (RATS) for early-stage non-small cell lung cancer is widely available at China's Class-3A tertiary hospitals, with published outcomes demonstrating shorter hospital stays and equivalent oncological results compared to conventional video-assisted approaches.
• Thyroid cancer surgery: China's thyroid surgery specialists are among the most experienced in the world, given the high prevalence of thyroid cancer in the Asia-Pacific region. Minimally invasive approaches, including endoscopic and robotic thyroidectomy, are routinely available with demonstrated advantages in cosmetic outcomes and surgical precision.

2.2 Technology Parity: The Myth That Western Hospitals Have Better Equipment

A persistent misconception among patients considering overseas cancer surgery is that Western hospitals possess superior surgical technology unavailable elsewhere. This is simply not accurate in 2025. China's Class-3A tertiary oncology hospitals are equipped with the same generation of surgical technology used at leading centers globally. This includes DaVinci Xi robotic surgical systems, intraoperative fluorescence imaging, advanced laparoscopic platforms, intraoperative ultrasound, navigational bronchoscopy, and molecular pathology laboratories performing real-time genomic analysis. In some cases — particularly in radiation oncology, which often accompanies surgical treatment — China's leading centers have invested in technology that remains rare even at major US academic medical centers.

MedBridge's vetting process for partner institutions specifically includes an equipment audit verifying the presence and operational status of the technologies relevant to each patient's planned procedure. We do not refer patients to institutions where equipment claims cannot be independently verified.

2.2.1 Multidisciplinary Tumor Boards: The Gold Standard of Cancer Care Planning

One of the most important — and least visible — determinants of cancer surgery quality is the multidisciplinary tumor board. In this structured clinical forum, surgeons, oncologists, radiologists, pathologists, and other specialists collectively review each patient's imaging, pathology, and clinical history before developing an individualized treatment plan. This process dramatically reduces the risk of undertreating or overtreating cancer, ensures that the optimal surgical approach is selected for each patient's specific tumor biology, and catches errors or oversights that any individual clinician might miss.

Multidisciplinary tumor boards are standard practice at every institution in MedBridge's partner network. Every international patient referred through MedBridge has their case reviewed by the full tumor board before any treatment decision is finalized — including patients who conduct their initial consultation via telemedicine from their home country.

3. China's Oncology Hospitals: The Case for Genuine International Confidence

For North American and European patients, the decision to trust a foreign healthcare system with a cancer surgery requires more than cost arguments. It requires concrete, independently verifiable evidence of institutional quality, regulatory oversight, and patient safety. This section addresses that need directly and honestly.

3.1 Accreditation, Regulation, and Quality Oversight in China's Hospital System

China's National Health Commission maintains a three-tier hospital classification system that is the most comprehensive national hospital quality framework in Asia. Class-3A hospitals — the designation held by every institution in MedBridge's oncology partner network — represent the highest tier of this system, meeting stringent standards for staffing qualifications, equipment provision, clinical protocol compliance, quality management systems, outcomes reporting, and patient safety infrastructure.

• China's Class-3A designation requires hospitals to maintain minimum standards across more than 600 individual quality indicators — a scope that exceeds the requirements of many Western accreditation frameworks.
• Several of China's leading cancer centers have received or are actively pursuing Joint Commission International (JCI) accreditation — the global gold standard for hospital quality held by institutions including Johns Hopkins Hospital and the Cleveland Clinic.
• China participates in the International Cancer Benchmarking Partnership and comparable international outcomes comparison frameworks, providing external validation of clinical performance data.
• Leading Chinese oncology centers are members of the Union for International Cancer Control (UICC) and maintain affiliations with international professional bodies including the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO).
• China's oncology research output is second globally in volume, with significant contributions to peer-reviewed journals including Nature Medicine, Cancer Cell, and The Lancet Oncology.

3.2 Surgeon Credentials and Training: An International Standard

A common concern among patients considering overseas surgery is whether Chinese surgeons have training credentials equivalent to their Western counterparts. For the institutions in MedBridge's partner network, the answer is emphatically yes. The surgical team leaders at China's premier oncology centers have, in most cases, completed fellowship training at internationally recognized institutions — including the MD Anderson Cancer Center, Memorial Sloan Kettering, the Royal Marsden Hospital, and leading European academic medical centers — in addition to their Chinese medical education and board certification.

Many hold dual board certifications, publish in English-language peer-reviewed journals, and serve on the editorial boards of international oncology publications. They are, by any reasonable measure, members of the global surgical oncology community — not practitioners operating outside it.

3.3 Language, Culture, and the International Patient Experience

One legitimate concern that patients raise about cancer surgery in China is the language and cultural barrier. This concern deserves a direct and honest answer. At China's top-tier hospitals, international patient departments are staffed by English-speaking medical professionals, and medical documentation is routinely produced in English for international patients. However, the experience is not identical to receiving care in a predominantly English-language healthcare system, and some differences in communication style and patient involvement norms do exist.

This is precisely why MedBridge's on-ground coordinator presence — bilingual professionals who attend every major consultation, facilitate real-time communication between patient and clinical team, and serve as the patient's dedicated advocate throughout their stay — is not a luxury add-on but an integral and essential component of the overseas cancer surgery experience we facilitate. We do not send patients into unfamiliar systems alone.

3.3.1 Telemedicine and Remote Second Opinion: Starting Without Leaving Home

Many patients are surprised to learn that they can receive a comprehensive oncological second opinion from China's leading specialists without travelling at all. Through MedBridge's secure telemedicine platform, patients can share imaging files, pathology reports, operative summaries, and treatment histories with partner oncologists in China, who provide detailed written second opinions in English within 5–7 business days. These opinions include the Chinese specialist's assessment of the diagnosis, proposed surgical approach, expected outcomes, and complete cost estimate — giving patients everything they need to make an informed decision before committing to travel.

4. The Real Numbers: A Comprehensive US vs. China Cancer Surgery Cost Breakdown

Cost transparency is one of MedBridge's core commitments. The figures in the table below represent verified cost ranges based on MedBridge's ongoing relationships with partner institutions and current pricing as of mid-2025. All China figures represent all-inclusive package costs covering pre-operative workup, the surgical procedure, anesthesia, hospital stay, pathology, and standard post-operative monitoring unless otherwise noted.

4.1 Understanding the All-Inclusive Package Model: What Is and Is Not Included

One of the most practically important differences between cancer surgery costs in China versus the United States is the billing model. In the US, patients receive separate bills from the hospital, the surgeon, the anesthesiologist, the assistant surgeon, the pathology laboratory, the radiology department, and any consulting specialists involved in their care. Each of these bills may be submitted to insurance separately, with different in-network or out-of-network determinations applying to each provider.

At MedBridge's partner centers in China, patients receive a single itemized package estimate covering all components of their care. Standard inclusions are: pre-admission consultations and imaging review, all pre-operative diagnostic testing required by the anesthesia team, the surgical procedure itself (including all surgeon, assistant, and anesthesiologist fees), hospital room and board for the expected length of stay, all post-operative nursing care and monitoring, standard pathology and molecular testing of the resected specimen, routine post-operative medications, and a defined number of follow-up consultations before discharge and departure.

What is typically not included — and is clearly disclosed upfront — includes: international flights and accommodation, any additional diagnostic testing required if unexpected findings are made during surgery, adjuvant therapy (chemotherapy, radiation, or immunotherapy) if required, and extended hospital stays beyond the package duration if complications arise. MedBridge provides patients with a detailed written disclosure of what is and is not included in every package estimate, ensuring there are no surprises.

4.2 Lifetime Financial Perspective: The True Cost Comparison

For patients who are considering the financial dimension of their cancer surgery decision, it is worth applying a lifetime perspective. A patient in the United States who undergoes a robotic radical prostatectomy and faces a total out-of-pocket cost of $15,000–$30,000 (after insurance) may then face additional costs for adjuvant hormone therapy, PSA monitoring, imaging surveillance, and management of any treatment side effects over a 10–15 year survivorship period. The surgical bill, while large, is just the beginning of the financial journey.

When patients access their initial cancer surgery through MedBridge's partner centers in China — at 60–70% less than US pricing — the savings freed up represent a meaningful buffer for the ongoing costs of cancer survivorship care, which they will continue to receive from their home oncologists. This is not simply about the surgical procedure in isolation; it is about the entire financial architecture of living with and beyond cancer.

5. The Most Common Cancer Surgeries Sought Abroad: What Patients Are Choosing and Why

Not all cancer surgeries are equally well-suited to the overseas treatment model. The best candidates are procedures where the surgery itself is the primary curative or definitive treatment, where the pre-operative workup can be substantially completed in the patient's home country, where recovery does not require extended in-country hospitalization beyond 2–3 weeks, and where follow-up monitoring can be meaningfully conducted by a home-country oncologist. The following cancer types represent the most frequently chosen overseas oncology surgery cases through MedBridge:

5.1 Prostate Cancer: The Robotic Prostatectomy Advantage Abroad

Prostate cancer surgery — specifically radical prostatectomy — is among the most sought-after overseas oncology procedures for North American and European men. The reasons are compelling: the procedure is well-standardized globally, the outcomes are highly surgeon-dependent, recovery is manageable, and the cost savings are substantial. A robotic radical prostatectomy in the United States typically costs $25,000–$45,000 out-of-pocket even with insurance, compared to $8,000–$15,000 all-inclusive through MedBridge's China partner centers.

China's urological oncology specialists have extensive experience with robotic prostatectomy, performing procedures on both Asian and international patients and demonstrating published outcomes in terms of continence recovery, erectile function preservation, and oncological control that are directly comparable to leading US and European centers. For men with localized or locally advanced prostate cancer who have been advised to consider surgery, the overseas option deserves serious consideration.

5.2 Colorectal Cancer: High-Volume Expertise and Cost-Effective Access

Colorectal cancer surgery — including right and left colectomy, anterior resection, and abdominoperineal resection — is among the highest-volume procedures at China's general and colorectal surgery centers. China's high burden of colorectal cancer has driven the development of exceptional surgical expertise, and the availability of robotic-assisted colorectal surgery at leading centers provides additional advantages in the technically demanding pelvic dissection required for rectal cancer surgery.

For patients who have received a colorectal cancer diagnosis and face a waiting period of weeks to months before surgery can be scheduled in their home country, the overseas option offers an additional benefit beyond cost savings: immediate access to surgical care without clinically significant delays. Given that colorectal cancer outcomes are strongly stage-dependent, timely surgery can have genuine clinical significance beyond the financial dimension.

5.3 Gynecological Oncology: Cervical, Endometrial, and Ovarian Cancer Surgery Abroad

Women diagnosed with cervical, endometrial, or early-stage ovarian cancer who require surgical staging and/or definitive resection represent a significant and growing proportion of MedBridge's international cancer surgery referrals. China's gynecological oncology departments at Class-3A tertiary hospitals offer robotic and laparoscopic radical hysterectomy, pelvic and para-aortic lymph node dissection, and cytoreductive surgery with outcomes data published in international gynecological oncology journals.

For women in countries where access to minimally invasive gynecological oncology surgery is limited — either by cost or by the availability of surgeons with appropriate robotic expertise — China's partner centers represent a genuinely meaningful upgrade in surgical quality alongside substantial cost savings.

5.3.1 Thyroid Cancer Surgery: A Straightforward Case for Overseas Care

Thyroid cancer surgery — particularly total thyroidectomy and central neck dissection for papillary and follicular thyroid cancer — represents one of the most straightforward cases for overseas surgical care. The procedure is well-standardized, recovery is rapid (most patients are discharged within 2–3 days), the pathology is well-characterized before surgery, and follow-up monitoring via thyroglobulin levels and ultrasound surveillance can be entirely conducted by a home-country endocrinologist. China's thyroid surgery specialists are among the most experienced in the world, with published expertise in nerve monitoring techniques that preserve laryngeal nerve function and minimally invasive endoscopic approaches that eliminate the neck scar entirely. At $3,500–$8,000 all-inclusive, compared to $10,000–$25,000 in the United States, the cost case is compelling.

6. Who Is the Right Candidate for Overseas Cancer Surgery? A Practical Assessment Framework

Not every cancer patient is an appropriate candidate for overseas surgical care, and honest guidance requires acknowledging this clearly. The decision to travel internationally for cancer surgery is significant, and it is not right for everyone. The following framework — developed from MedBridge's experience supporting international cancer surgery patients — helps identify who is most likely to benefit.

6.1 The Pre-Departure Preparation: What Must Be Done Before You Travel

Responsible overseas cancer surgery preparation begins well before any international travel is arranged. MedBridge's pre-engagement protocol requires that every cancer surgery patient complete the following steps before a referral to a partner institution is confirmed:

6.2 Age, Fitness, and Medical Travel: What the Evidence Shows

A concern commonly raised about overseas cancer surgery — particularly by older patients or their families — is whether age or pre-existing health conditions make international medical travel inappropriate. The evidence suggests that age alone is not a contraindication to medical travel for cancer surgery; functional status and medical fitness for surgery are the relevant variables, and these are assessed the same way whether surgery is performed domestically or abroad. Patients in their 60s, 70s, and even 80s regularly undergo major cancer surgery at MedBridge's partner centers, provided they meet the same fitness criteria applied to any surgical candidate. MedBridge's pre-engagement protocol includes a structured fitness-for-travel assessment as a standard component.

7. Navigating Safety, Quality Control, and Continuity of Care for Overseas Cancer Surgery

For patients who have moved beyond the initial question of whether overseas cancer surgery is appropriate for them and are now asking how to do it safely, this section addresses the specific safety and quality assurance mechanisms that distinguish responsible overseas cancer surgery from medical tourism risk. These are not theoretical considerations — they are practical protocols that MedBridge implements for every patient in our network.

7.1 What Happens If Something Goes Wrong: Complication Management Abroad

The possibility of surgical complications is a reality of any major cancer operation, whether performed at home or abroad. For patients considering overseas surgery, understanding how complications would be managed is an essential part of informed decision-making. Surgical complications following cancer surgery at MedBridge's partner centers are managed within those centers — which maintain ICU facilities, interventional radiology capabilities, and specialist consultation services that can address the full spectrum of potential post-operative complications. Patients are not discharged and sent home at the first sign of a problem.

In the rare event of a complication that requires extended hospitalization beyond the planned recovery period, MedBridge's on-ground coordinators manage all logistics — including communication with the patient's family at home, insurance notification where applicable, and accommodation management — so that the patient and their support person can focus entirely on recovery.

7.2 Pathology Reports, Medical Records, and Documentation: What You Take Home

When a patient returns home from cancer surgery at a MedBridge partner center, they bring with them a comprehensive package of medical documentation that their home-country oncologist can use to plan and manage ongoing care. This package includes: a detailed operative report describing the surgical approach, findings, lymph node yield, and margin status; the pathology report from the resected specimen, including all molecular and immunohistochemical markers performed; pre- and post-operative imaging; anesthesia records; discharge summary; and a recommended follow-up protocol prepared by the operating surgeon.

All documentation is produced in English and — where relevant — includes the original Chinese-language version alongside a certified English translation. MedBridge coordinates the preparation and delivery of this documentation package as a standard service, ensuring nothing is lost in translation or administrative transition.

7.3 Insurance Considerations: What International Patients Need to Know

International health insurance policies increasingly cover treatment at internationally accredited hospitals abroad, and China's Class-3A tertiary hospitals — where MedBridge's partners are based — meet the accreditation criteria of most international insurers. We strongly recommend that every patient review their insurance policy terms before making any commitment and work with their insurer to pre-authorize treatment where possible. MedBridge's coordination team has extensive experience supporting insurance pre-authorization processes and can provide clinical documentation in the formats required by major international insurers, including Cigna Global, Allianz Care, AXA PPP Healthcare, and Bupa International.

7.3.1 Medical Second Opinion Services: Using Overseas Expertise Without Surgery Abroad

Not every patient who contacts MedBridge proceeds to overseas surgery. Some patients are primarily seeking a second opinion from internationally experienced oncological surgeons on their diagnosis and proposed treatment plan. MedBridge facilitates formal written second opinions from partner institution surgical teams as a standalone service — without any obligation to proceed to treatment. These second opinions have proven valuable not only for patients considering overseas care but also for those who ultimately choose to proceed with surgery in their home country but want independent expert validation of their treatment plan before doing so.

8. How MedBridge Makes Overseas Cancer Surgery Safe, Supported, and Effectively Navigated

MedBridge exists because the gap between a patient knowing that better, more affordable cancer surgery exists abroad and actually accessing that care safely and effectively is significant. Navigating an unfamiliar healthcare system in a foreign country — while managing the emotional weight of a cancer diagnosis, coordinating with home-country physicians, and maintaining family and professional commitments — requires a level of logistical and clinical support that most individuals cannot provide for themselves.

8.1 The Complete MedBridge Overseas Cancer Surgery Journey

8.2 How MedBridge Selects and Monitors Partner Oncology Institutions

Every oncology institution accessible through MedBridge has undergone a rigorous multi-stage vetting process before being included in our partner network. This process includes: formal verification of Class-3A hospital designation and any additional international accreditations held; independent review of surgeon credentials, board certifications, and published case volume and outcomes data for the specific procedures relevant to our referral patterns; assessment of English-language communication infrastructure within the international patient department; evaluation of pricing transparency and billing practices; review of medical record production quality and turnaround time for international patient documentation; and on-site inspection by a member of MedBridge's medical advisory board.

8.3 Our Vetting Standard: The Non-Negotiable Requirements

• Class-3A tertiary hospital designation verified with China's National Health Commission registry
• Minimum documented surgical case volume for the procedure types relevant to international referrals
• English-speaking medical liaison and patient coordination staff available during all hospital operating hours
• On-site ICU and interventional radiology capability for complication management
• Comprehensive molecular pathology laboratory with published turnaround times
• Multidisciplinary tumor board meeting at minimum weekly with documented case review records
• Transparent, itemized all-inclusive pricing with written disclosure of what is and is not included
• Formal English-language medical record production as a standard service for international patients